Kjell Thörnbring, born 1958

CEO, Vice President Sales & Marketing
Mr Thörnbring has been employed by Artimplant since 2011.
Kjell Thörnbring is B.Sc. in Business Administration from the University of Gothenburg and has most recently worked as CFO at Din Bostad Sverige AB (publ), which was acquired by Fastighets AB Balder (publ). He was formerly CFO at Borås Wäfveri AB (publ), CEO at Elanders AB (publ) and has held a number of other finance manager positions.

Susan Linke, born 1969

Vice President Finance
Ms Linke has been employed by the company since 2007 and has earlier been an accountant in the company. She has a background as Financial Manager.  

Holdings in Artimplant:
1 100 Series B stock units.
Employee incentive call options 8255 program 2007/2012, 12313 program 2008/2013, 1440 program 2009/2014.

Katrin Gisselfält, born 1969

Vice President R&D, Ph.D.
Dr. Gisselfält has been employed by Artimplant since 1995. She is one of the key scientists behind Artelon®.
Katrin Gisselfält holds a Ph.D. degree in Polymer Chemistry, Chalmers University of Technology, Gothenburg. The primary field of research has been synthesis, characterization and processing of degradable poly(urethane urea)s and their use as biomaterials.

Holdings in Artimplant:
30 000 Series B stock units.
Employee incentive call options 44 799 program 2007/2012, 40 000 program 2008/2013, 44 000 program 2009/2014.

Hanna Stenhamre, born 1978

Vice President Clinical Affairs, Ph.D.
Dr. Stenhamre has been employed by Artimplant since 2005.
Hanna Stenhamre holds a Ph.D. degree in Bioscience, Chalmers University of Technology, Gothenburg. The primary field of research has been cartilage cell therapy; by means how cellular behaviour can be influenced by external factors such as the design of scaffolds.

Holdings in Artimplant:
4 000 Series B stock units.
Employee incentive call options 8255 program 2007/2012, 12313 program 2008/2013, 11699 program 2009/2014.

Bengt Furberg, born 1941

Vice President Medical Affairs, M.D., Ph.D., Associate Professor
Dr. Furberg has been engaged as Vice President Medical Affairs since December 21, 2006.
Dr. Furberg has a wide-ranging medical background and long experience from the industry. For more than ten years Dr. Furberg was Medical Director of GlaxoWellcome Sweden and his latest assignment was as Medical Director of Bactiguard AB. He has many years experience of international requirements for obtaining regulatory clearances within pharmaceuticals and medical devices. Moreover, Dr. Furberg has worked as a medical professional, both as head of a department of clinical physiology and as head of an occupational health centre.
Dr. Furberg has published some 40 articles, among others in sports medicine and clinical trials, an area in which he also writes educational literature. Dr. Furberg holds a Ph.D. from the University of Uppsala, Sweden.

Other assignments:
Member of the Board of Dignitana AB and Immunicum AB. Senior medical advisor for Bactiguard AB.

Holdings in Artimplant:
80 000 Series B stock units. No options in Artimplant.